Tohoku University Technology: Pharmaceutical Composition for the Prevention or Treatment of Fibrosis: T10-134
Suppress the onset and progression of pulmonary fibrosis!!
Pulmonary fibrosis is a disease in which the lungs become fibrotic, shrink, and lose function, leading to inadequate gas exchange. As pulmonary fibrosis progresses, it ultimately results in respiratory distress and can be fatal. There are currently no effective drugs or treatments established for this disease, and the survival period for affected patients is said to be 2 to 3 years. The inventor of this invention has discovered that stanniocalcin 1 (STC1), a hormone in the body, has an inhibitory effect on the onset and progression of pulmonary fibrosis. STC1 is thought to exhibit anti-fibrotic effects by reducing endoplasmic reticulum stress, which is one of the causes of fibrosis, and the associated production of TGF-β1.
- Company：Tohoku Techno Arch Co., Ltd.
- Price：Other
